Navigation Links
Soliris Effective in PNH Patients With History of Aplastic Anemia,and Myelodysplastic Syndromes

undergoing therapy with Soliris (p<0.001). Patients with a history of AA or MDS also reported a noticeable improvement in fatigue and overall quality-of- life, similar to the clinical improvements reported by the overall PNH patient population in the TRIUMPH and SHEPHERD studies. Patients with a history of AA or MDS had an elevated rate of thromboembolic events prior to entering the studies (11.13 events per 100 patient-years; n=59) and the rate with Soliris treatment was 1.04 events per 100 patient-years (P<0.001). Soliris appeared to be safe and well-tolerated when administered to PNH patients with a history of AA or MDS, similar to results in the overall population in the TRIUMPH and SHEPHERD studies.(8)

About PNH

PNH is an acquired genetic blood disorder defined by hemolysis, in which patients' red blood cells are destroyed by complement, a component of the body's immune system. PNH affects an estimated 8,000 to 10,000 people in North America and Europe.(9) PNH often strikes people in the prime of their lives, with an average age of onset in the early 30's.(10) Ten percent of all patients first develop symptoms at 21 years of age or younger.(2) PNH develops without warning and can occur in men and women of all races, backgrounds and ages. PNH often goes unrecognized, with delays in diagnosis often ranging from one to more than 10 years.(7) The estimated median survival for PNH patients is between 10 and 15 years from the time of diagnosis.(5)(11)

About Soliris

Soliris is the first therapy approved by the U.S. Food and Drug Administration for the treatment of PNH. Soliris is indicated for the treatment of patients with PNH to reduce hemolysis. In April the Committee for Human Medicinal Products (CHMP) of the European Medicines Agency (EMEA) adopted a positive opinion recommending marketing authorization for Soliris for the treatment of all patients with PNH. Final EU approval is expected in June or July 2007.

Prior to approval o
'"/>




Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Studies Show Efficacy and Safety of Alexions Soliris in Broad Population of PNH Patients
2. New Study Shows That Extending Prophylaxis With Clexane / Lovenox (enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10 Days for Reducing the Risk of Venous Thromboembolism (VTE) in Acutely ill Medical Patients With Reduced Mobility
3. Eurands Zentase Effective in Treating Exocrine Pancreatic Insufficiency, Studies Show
4. Cimzia Effective in Reducing Signs and Symptoms of Rheumatoid Arthritis
5. Gabapentin Shown Effective for Fibromyalgia Pain
6. ApoCells Cancer Predictive Index Helps Oncologists Select the Most Effective Targeted Drug Therapy
7. Roxro Pharma’s Novel Intranasal Pain Reliever Effective, Well Tolerated in Phase 3 Study
8. XYOTAX More Cost Effective With Fewer Side Effects Than Gemcitabine or Vinorelbine in Treating Non-Small Cell Lung Cancer
9. Repeated Radioimmunotherapy With 131I-Labetuzumab Appears Safe and Effective in Colorectal Cancer with Liver Metastases
10. Biotheras Imprime PGG Enhanced Effectiveness of Avastin in Cancer Study
11. Targanta Study Shows Oritavancin Treatment Effective in a Mouse Model of Anthrax
Post Your Comments:
(Date:9/17/2014)... Sept. 17, 2014  The law firm McElroy, ... that it will serve as host for "Show ... the Risks of Healthcare Reform," a one-day conference ... delivery systems, reimbursement, compliance and enforcement in a ... Logo -  http://photos.prnewswire.com/prnh/20140916/146606 Logo -  ...
(Date:9/17/2014)... Sept. 17, 2014  Aratana Therapeutics, Inc. (NASDAQ: ... on licensing, developing and commercializing innovative biopharmaceutical products ... its public offering of 4,500,000 shares of its common stock ... per share. Aratana has granted the underwriters a ... 675,000 shares of its common stock. ...
(Date:9/17/2014)... CARLSBAD, Calif. , Sept. 17, 2014 /PRNewswire/ ... ) announced that it has earned a $4 ... AKAO ) associated with the initiation of ... with serious multi-drug resistant (MDR), gram-negative bacterial infections.  ... superiority study to evaluate the efficacy and safety ...
Breaking Medicine Technology:Three Leading Healthcare Organizations Sponsor Conference to Examine Opportunities and Risks of Healthcare Reform for Providers 2Aratana Therapeutics, Inc. Announces Pricing of Public Offering 2Isis Pharmaceuticals Earns $4 Million from Achaogen for the Initiation of a Phase 3 Study of Plazomicin 2Isis Pharmaceuticals Earns $4 Million from Achaogen for the Initiation of a Phase 3 Study of Plazomicin 3
(Date:9/17/2014)... East Brunswick, NJ (PRWEB) September 17, 2014 ... its Static Application Security Testing (SAST) tool, at AppSec ... the 19th from 9 am to 6 pm at ... 2014 is one of the leading software security conferences ... SPARROW is a tool that provides developers and managers ...
(Date:9/17/2014)... Journal of Surgery ( IJS ) has announced that ... after 24 months published journal issues become available for all ... is to improve surgical knowledge and patient care and it ... will improve efforts to achieve this. , Professor David ... always been a great place for authors to publish and ...
(Date:9/17/2014)... coupled to a progressive decline in signal transduction and ... at Karolinska Institutet in Sweden. The finding, which is ... new molecular mechanism underlying age-related impairment of insulin-producing cells ... risk factors for many diseases, and type 2 diabetes ... an increased risk of developing type 2 diabetes if ...
(Date:9/17/2014)... Representatives with Capitol Pain Institute announced ... League Event at the Four Seasons in Austin, Texas. , ... honor to be a sponsor for this great event,” said ... went on to explain that the event, the Torch of ... members at the Four Seasons to honor Torch of Liberty ...
(Date:9/17/2014)... In a continuing effort to protect local athletes ... Shield of the South Shore has partnered for the ... Athletic Association to treat area fields in preparation for ... dusk, prime mosquito feeding time, the exposure to mosquito-borne ... involved in outdoor athletic activities. , Rob and Lisa ...
Breaking Medicine News(10 mins):Health News:Fasoo to Introduce Their Testing Tool to Improve Software Security and Quality at AppSec USA 2014 2Health News:Mechanism behind age-dependent diabetes discovered 2Health News:Capitol Pain Institute Sponsoring an Anti-Defamation League Event & Awards Dinner 2Health News:Mosquito Shield of South Shore Again Partners with Hanover Youth Athletic Association 2
... obstacles towards progress in the developing world is the ... been seriously addressed by the public health community. ... People, Forgotten Diseases, published by ASM Press. , Some ... too long been ignored. Parasitic and bacterial diseases ...
... Ohio, April 8, 2008 Cardinal Health,Inc. (NYSE: CAH ... safety and productivity of health care, plans to release third-quarter,results ... opening of trading,on the New York Stock Exchange., The ... 1 at,8:30 a.m. EDT to discuss results of the quarter. ...
... small trial, new study finds no effect , , TUESDAY, ... don,t help prevent relapses in patients with Crohn,s disease, ... of the Journal of the American Medical Association ... lead author Dr. Brian Feagan, professor of medicine and ...
... tea have long held a place in traditional medicine in ... health and long life and for the treatment of specific ... the bodys immune functions and hold the potential for treatment ... Now a new study by Chinese scientists found that combining ...
... 8, 2008 The numbers tell the,story, Vicki Hoak, ... the Senate Aging and Youth Committee today.,The Medicaid reimbursement ... is $67,000,per person. For an acute care hospital, the ... is just $21,000., Since the Governor and legislators ...
... Light San Diego Pink Day, SAN DIEGO, April ... world,s largest grassroots network of breast cancer survivors and,activists ... San Diego Affiliate will award $960,000 in grants to ... underinsured women and men in,San Diego receive breast cancer ...
Cached Medicine News:Health News:Forgotten diseases key to lifting developing world from poverty, destitution and despair 2Health News:Cardinal Health to Announce Third-Quarter Results on May 1 2Health News:Cardinal Health to Announce Third-Quarter Results on May 1 3Health News:Omega-3 Fatty Acids Won't Prevent Crohn's Relapse 2Health News:Omega-3 Fatty Acids Won't Prevent Crohn's Relapse 3Health News:Extracts from reishi mushroom and green tea shows synergistic effect to slow sarcoma 2Health News:Since Governor and Legislators Agree on Value of Homecare, Advocacy Group Says Time is Now to Make it Available to More Pennsylvanians 2Health News:Since Governor and Legislators Agree on Value of Homecare, Advocacy Group Says Time is Now to Make it Available to More Pennsylvanians 3Health News:Susan G. Komen for the Cure Awards San Diego Organizations Nearly $1 Million to Fight Breast Cancer 2Health News:Susan G. Komen for the Cure Awards San Diego Organizations Nearly $1 Million to Fight Breast Cancer 3Health News:Susan G. Komen for the Cure Awards San Diego Organizations Nearly $1 Million to Fight Breast Cancer 4
Prostate biopsy transducer....
Multi-frequency, HST, linear transducer with a longer (60mm) footprint. Available with puncture adapter and water path. This transducer incorporates ALOKAs exclusive Hemispheric Sound Technology and ...
... high frequency (13Mhz) ... and superficial imaging. ... Hemispheric Sound Technology ... This multi-frequency transducer ...
... an excellent choice for a ... wide scan angle. With muliple ... designed for a wide view ... versatility of this transducer provides ...
Medicine Products: